Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
26.8M
-
Number of holders
-
44
-
Total 13F shares, excl. options
-
8.23M
-
Shares change
-
+1.05M
-
Total reported value, excl. options
-
$27.1M
-
Value change
-
+$3.4M
-
Put/Call ratio
-
0.02
-
Number of buys
-
13
-
Number of sells
-
-22
-
Price
-
$3.29
Significant Holders of Eton Pharmaceuticals, Inc. - Common Stock (ETON) as of Q2 2024
53 filings reported holding ETON - Eton Pharmaceuticals, Inc. - Common Stock as of Q2 2024.
Eton Pharmaceuticals, Inc. - Common Stock (ETON) has 44 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8.23M shares
of 26.8M outstanding shares and own 30.65% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (2.4M shares), VANGUARD GROUP INC (1.03M shares), Nantahala Capital Management, LLC (941K shares), Westside Investment Management, Inc. (585K shares), Acuitas Investments, LLC (580K shares), PARADIGM CAPITAL MANAGEMENT INC/NY (300K shares), BlackRock Inc. (282K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (253K shares), Parkman Healthcare Partners LLC (253K shares), and GEODE CAPITAL MANAGEMENT, LLC (240K shares).
This table shows the top 44 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.